5 novel immuno-oncology targets to know before ASCO

5 novel immuno-oncology targets to know before ASCO

Source: 
Biopharma Dive
snippet: 

The failure of Incyte's epacadostat last year cooled enthusiasm for cancer immunotherapies designed to build upon the strong foundation laid by the PD-(L)1 inhibitor class, now led by Merck & Co.'s Keytruda.